Abstract: Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system and represents one of the most common causes of chronic neurologic disability. Until recently, major treatments have relied on agents by injection which can induce injection-related adverse events. The parenteral route of administration may affect the compliance with therapy in multiple sclerosis. Therefore, there is a need for the development of oral agents. The research of five oral drugs (cladribine, fingolimod, teriflunomide, laquinimod and dimethyl fumarate), is carrying out in Phase Ⅲ study. In this article, we review the undergoing clinical trials of these five oral agents.

Key words: Multiple sclerosis, Drug therapy, Clinical trials, Review

摘要： 目前治疗多发性硬化的药物剂型以皮下或肌内注射为主，存在注射部位皮肤红肿、应用不方便等缺点，导致患者依从性较差。5 种新型多发性硬化口服药物克拉屈滨、芬戈莫德、特立氟胺、拉喹莫德和富马酸二甲酯业已进入Ⅲ期临床试验，期待能够提高患者依从性。

关键词: 多发性硬化, 药物疗法, 临床试验, 综述